Guide Calculator Compounds Blog Get Milligram
PHARMACOKINETICS

Compound
Half-Life Chart

Compare pharmacokinetic profiles across peptides, GLP-1 agonists, testosterone esters, and more. Half-life determines dosing frequency, time to steady state, and how your levels fluctuate between doses.

Filter:
GLP-1 Agonists
161h (6.7d)
120h (5d)
120h (5d)
Testosterone Esters
Test Undecanoate
1,272h (53d)
192h (8d)
108h (4.5d)
Test Propionate
19h
Healing Peptides
4h
2h
30 min
GH Peptides
192h (8d)
Ipamorelin
2h
CJC-1295 no DAC
30 min
Other
2.5h
45 min
15 min

What Is Half-Life?

In pharmacokinetics, half-life is the time it takes for the concentration of a compound in your blood to decrease by exactly 50%. It is one of the most important parameters governing how a compound behaves in your body.

Half-life directly determines dosing frequency. Compounds with short half-lives (like BPC-157 at 30 minutes) are typically dosed daily because they clear quickly. Compounds with long half-lives (like semaglutide at 6.7 days) can be dosed once a week because they remain active for extended periods.

Time to Steady State ≈ 5 × t½

Steady state is reached after approximately 5 half-lives of consistent dosing. At this point, the amount of compound entering your system equals the amount being cleared with each dose cycle. This is when blood levels stabilize into a predictable pattern and the compound reaches its full pharmacokinetic potential.

The range of half-lives across commonly used compounds is enormous — from 15 minutes (glutathione) to 53 days (testosterone undecanoate). This 5,000x range is why dosing frequency varies so dramatically between compounds and why tracking levels matters.

Steady-State Reference Table

Time to reach steady state (5 × half-life) and typical dosing frequency for each compound.

Compound Half-Life Steady State Typical Frequency
Testosterone Undecanoate 1,272h (53d) 265 days Every 10-14 weeks
CJC-1295 with DAC 192h (8d) 40 days 1-2x per week
Testosterone Cypionate 192h (8d) 40 days 1-2x per week
Semaglutide 161h (6.7d) 33.5 days Once weekly
Tirzepatide 120h (5d) 25 days Once weekly
Retatrutide 120h (5d) 25 days Once weekly
Testosterone Enanthate 108h (4.5d) 22.5 days 1-2x per week
Testosterone Propionate 19h 4 days Every other day
GHK-Cu 4h 20 hours Once daily
PT-141 2.5h 12.5 hours As needed
TB-500 2h 10 hours Once daily
Ipamorelin 2h 10 hours 2-3x daily
NAD+ 45 min 3.75 hours Once daily
BPC-157 30 min 2.5 hours 1-2x daily
CJC-1295 no DAC 30 min 2.5 hours 2-3x daily
Glutathione 15 min 1.25 hours Once daily

Frequently Asked Questions

Common questions about compound half-lives and pharmacokinetics.

A compound's half-life is the time it takes for the concentration in your body to decrease by 50%. For example, if a peptide has a 2-hour half-life, half of the administered dose will be cleared after 2 hours, 75% after 4 hours, 87.5% after 6 hours, and so on. This is a fundamental pharmacokinetic parameter that determines how long a compound remains active and how frequently it needs to be administered.
Compounds with shorter half-lives need more frequent dosing to maintain stable blood levels. A peptide with a 30-minute half-life (like BPC-157) is typically dosed daily, while a GLP-1 agonist with a 161-hour half-life (like semaglutide) can be dosed once weekly. The goal is to maintain therapeutic levels without excessive peak-to-trough variation. Shorter half-life compounds naturally have wider swings between peak and trough levels.
Steady state is reached after approximately 5 half-lives of consistent dosing. At this point, the amount entering the body equals the amount being cleared with each dose cycle. For testosterone enanthate (108h half-life), steady state takes about 22.5 days. For semaglutide (161h half-life), it takes approximately 33.5 days or about 5 weeks. This is why it often takes several weeks before you can fully evaluate how a protocol is performing.
Many peptides are rapidly broken down by enzymes in the blood (proteases) and cleared by the kidneys due to their small molecular size. This is why peptides like BPC-157 (30 min), glutathione (15 min), and CJC-1295 without DAC (30 min) have very short half-lives. Modified versions — like CJC-1295 with DAC — use chemical modifications (Drug Affinity Complex) to resist enzymatic breakdown, extending the half-life dramatically from 30 minutes to 8 days.
Among the compounds tracked in this chart, testosterone undecanoate has the longest half-life at approximately 1,272 hours (53 days), primarily used in long-acting injectable TRT formulations. Among peptides and GLP-1 agonists, CJC-1295 with DAC (192h / 8 days) and semaglutide (161h / 6.7 days) have the longest half-lives, which is why both can be administered on a weekly or less frequent schedule.
The route of administration can influence the effective half-life by changing the absorption rate. Subcutaneous injections create a depot effect that slows absorption, effectively extending the duration of action compared to intravenous administration. Oral peptides generally have shorter effective half-lives due to first-pass metabolism in the liver. The half-life values shown in this chart reflect the most common route of administration for each compound.